Gene expression testing helps determine chemotherapy needs for hormone receptor-positive breast cancer, optimizing treatment ...
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
Clinical Trials Arena on MSN20d
AstraZeneca reports positive outcomes from breast cancer combo therapy trialAstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-line ...
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
MedPage Today on MSN4d
Add-On Metformin Promising in ER-Positive Endometrial CancerAdding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...
A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...
Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...
All patients received an aromatase inhibitor and a CDK4/6 inhibitor—either Lilly’s Verzenio, Novartis’ Kisqali or Pfizer’s Ibrance—as their first-line treatment. Physicians monitored ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback